Search Result

Results for "

degradation efficiency

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (2) Apoptosis (2) Biochemical Assay Reagents (1) DNA/RNA Synthesis (1) Endogenous Metabolite (2) Endonuclease (1) Enterovirus (2) Histone Acetyltransferase (2) IKK (1) IKZF Family (1) Isotope-Labeled Compounds (1) Molecular Glues (1) NOD-like Receptor (NLR) (2) Potassium Channel (1) PROTAC Linkers (1) PROTACs (1)
By Research Areas:	Cancer (7) Infection (2) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112557

PROTAC TBK1 degrader-2	PROTACs IKK	Cancer
PROTAC TBK1 degrader-2 is a Ligands for Target Protein for PROTAC. PROTAC TBK1 degrader-2 is a potent degrader based on the serine/threonine kinase TANK-binding kinase 1 (TBK1) (DC₅₀=15 nM; K_d=4.6 nM) with a maximum efficiency of 96%. PROTAC TBK1 degrader-2 also targets to IkB kinase IKKε (IC₅₀=8.7 nM), with low selectivity over TBK1 (IC₅₀=1.3 nM) .

HY-149433

BWA-522	Androgen Receptor Apoptosis	Cancer
BWA-522 is an orally available small molecule protein-targeting chimera (PROTACs) with significant degradation effect on AR-FL and AR-V7. BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor (Androgen Receptor) and induces apoptosis in PC cells. BWA-522 inhibits tumor growth in LNCaP xenograft model studies (60 mg/kg, po; TGI=76%). The efficiencies of BWA-522 in degrading AR-V7 and AR-FL were 77.3% (1 μM) and 72.0% (5 μM) in VCaP and LNCaP cells, respectively .

HY-154818

Bovine Serum Albumin, Acetylated Ac-BSA	Biochemical Assay Reagents	Others
Bovine Serum Albumin, Acetylated (Ac-BSA) is a polypeptide of known structure with strong antigenicity. Bovine Serum Albumin, Acetylated produced a significant immune response, validating the accuracy and reliability of the experimental method. Bovine Serum Albumin, Acetylated can be used as a positive control substance in ELISA or WB experiments, and can be used in experiments with acetylated lysine monoclonal or polyclonal antibodies. Bovine Serum Albumin, Acetylated also improves encapsulation efficiency at low concentrations of PLGA, a polymer for biopharmaceutical delivery with biocompatibility, degradability, and controlled release properties .

HY-W019670

N4-Acetylcytidine 1 Publications Verification	Endogenous Metabolite Histone Acetyltransferase Enterovirus NOD-like Receptor (NLR)	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity .

HY-108858

Dornase alfa 1 Publications Verification rhDNase	DNA/RNA Synthesis Endonuclease	Inflammation/Immunology
Dornase alfa (rhDNase) is a recombinant human deoxyribonuclease I (rhDNase) that can specifically degrade extracellular DNA. Dornase alfa catalyzes the cleavage of DNA released by neutrophils in respiratory mucus, reduces sputum viscosity, thereby improving mucus clearance efficiency, reducing airway obstruction and alleviating inflammatory responses. Dornase alfa can be used to improve lung function (such as FEV_1) in cystic fibrosis (CF), reduce the risk of acute pulmonary exacerbations, and has good in vivo tolerability. Dornase alfa acts locally on the respiratory tract through aerosol inhalation, specifically improving the high viscosity of mucus caused by DNA accumulation and related respiratory symptoms .

HY-W753593

N4-Acetylcytidine-13C5	Isotope-Labeled Compounds Enterovirus NOD-like Receptor (NLR) Histone Acetyltransferase Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
N4-Acetylcytidine- ¹³C₅ is the ¹³C-labeled N4-Acetylcytidine (HY-W019670). N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity .

HY-W012935

Piperidine-4-carbaldehyde Piperidine-4-carboxaldehyde	PROTAC Linkers	Cancer
Piperidine-4-carbaldehyde (Piperidine-4-carboxaldehyde) is a PROTAC Linker. Piperidine-4-carbaldehyde can be used to optimize combined with the target protein affinity, thus improve the PROTAC the molecular degradation efficiency. Piperidine-4-carbaldehyde can be used in the CDK2 PROTACs (HY-161708) .

HY-172930

PVTX-405	Molecular Glues IKZF Family Potassium Channel	Inflammation/Immunology Cancer
PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC₅₀ of 0.7 nM and a D_max of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC₅₀ of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn ^391V C57BL/6 mice .

HY-149434

PROTAC AR-NTD degrader 1	Androgen Receptor Apoptosis	Cancer
PROTAC AR-NTD antagonist 1 (compound 18) is a small molecule protein-targeting chimera (PROTACs) targeting the Androgen Receptor AR-V7. PROTAC AR-NTD antagonist 1 antagonizes the N-terminal domain of AR (AR-NTD), degrades AR-V7 protein, and induces apoptosis in prostate cancer (PC) cells. The efficiencies of PROTAC AR-NTD antagonist 1 in degrading AR-V7 in VCaP cells were 62.2% (1 μM) and 71.1% (5 μM), respectively .

Cat. No.	Product Name

HY-L151

PROTAC Library	377 compounds
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy. MCE supplies a unique collection of 377 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

PROTAC Library

377 compounds

PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy.

MCE supplies a unique collection of 377 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

HY-L140

Withdrawn Drug Compound Library	218 compounds
Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug. Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications. MCE has sorted out 218 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

Withdrawn Drug Compound Library

218 compounds

Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug.

Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications.

MCE has sorted out 218 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

Cat. No.	Product Name	Type

HY-154818

Bovine Serum Albumin, Acetylated Ac-BSA	Native Proteins
Bovine Serum Albumin, Acetylated (Ac-BSA) is a polypeptide of known structure with strong antigenicity. Bovine Serum Albumin, Acetylated produced a significant immune response, validating the accuracy and reliability of the experimental method. Bovine Serum Albumin, Acetylated can be used as a positive control substance in ELISA or WB experiments, and can be used in experiments with acetylated lysine monoclonal or polyclonal antibodies. Bovine Serum Albumin, Acetylated also improves encapsulation efficiency at low concentrations of PLGA, a polymer for biopharmaceutical delivery with biocompatibility, degradability, and controlled release properties .

Bovine Serum Albumin, Acetylated

Ac-BSA

Native Proteins

Bovine Serum Albumin, Acetylated (Ac-BSA) is a polypeptide of known structure with strong antigenicity. Bovine Serum Albumin, Acetylated produced a significant immune response, validating the accuracy and reliability of the experimental method. Bovine Serum Albumin, Acetylated can be used as a positive control substance in ELISA or WB experiments, and can be used in experiments with acetylated lysine monoclonal or polyclonal antibodies. Bovine Serum Albumin, Acetylated also improves encapsulation efficiency at low concentrations of PLGA, a polymer for biopharmaceutical delivery with biocompatibility, degradability, and controlled release properties .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W019670

N4-Acetylcytidine 1 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Histone Acetyltransferase Enterovirus NOD-like Receptor (NLR)
N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity .

Cat. No.	Product Name	Chemical Structure

HY-W753593

N4-Acetylcytidine-13C5
N4-Acetylcytidine- ¹³C₅ is the ¹³C-labeled N4-Acetylcytidine (HY-W019670). N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity .

N4-Acetylcytidine-13C5

N4-Acetylcytidine- ¹³C₅ is the ¹³C-labeled N4-Acetylcytidine (HY-W019670). N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks